Spero Therapeutics, Inc.

SPRO · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$68,566$22,806-$46,415-$89,756
Dep. & Amort.$2$367$1,547$1,117
Deferred Tax$0$0$0$0
Stock-Based Comp.$7,793$7,932$0$0
Change in WC$36,284-$70,375$22,087$12,862
Other Non-Cash$1,043$6,275$15,050$11,430
Operating Cash Flow-$23,444-$32,995-$7,731-$64,347
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$39
Inv. Purchases$0$0-$26,970-$43,915
Inv. Sales/Matur.$0$0$60,777$51,548
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0$0$33,807$7,672
Financing Activities
Debt Repay.$0$0-$54,485$47,480
Stock Issued$0$221$24,932$36,570
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$0$221-$29,553$84,050
Forex Effect$0$0$0-$0
Net Chg. in Cash-$23,444-$32,774-$3,477$27,375
Supplemental Information
Beg. Cash$76,333$109,107$112,584$85,209
End Cash$52,889$76,333$109,107$112,584
Free Cash Flow-$23,444-$32,995-$7,731$0